ReviewJournal of pathology and translational medicine2024
Cytologic hallmarks and differential diagnosis of papillary thyroid carcinoma subtypes.
Review in Journal of pathology and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Guideline
- Interpretable SVM-Based Integrated Ultrasound Model for Preoperative Thyroid Nodule Subtype Classification: Improved Identification of Follicular Variant Papillary Thyroid Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Single-cell reveals age-dependent epithelial reprogramming and EMT vulnerability in THCA.Endocrine-related cancer · 2026Article
- Clinicopathological profile of high-grade differentiated thyroid carcinoma in an Indonesian tertiary hospital.Journal of pathology and translational medicine · 2026Article
- Advantages of thyroid core needle biopsy: an emerging selective first-line biopsy modality.Ultrasonography (Seoul, Korea) · 2026Article
- Clinical Behavior of Aggressive Variants of Papillary Thyroid Carcinoma: A Retrospective Case-Control Study.Cancers · 2026Article
- Papillary thyroid carcinoma in thyroglossal duct cyst: a Peruvian case series.Endocrinology, diabetes & metabolism case reports · 2026Article
- Fine Needle Aspiration Cytology of Papillary Thyroid Carcinoma: Association of Cytological Features with Tumor Invasiveness in 43 Cases.Iranian journal of pathology · 2026Article
- The combined detection of aspiration biopsy, computed tomography and BRAFV600E gene has high diagnostic value for papillary thyroid carcinoma.Archives of endocrinology and metabolism · 2025Article
- Article
- Propensity score-matched analysis of the '2+2' parathyroid strategy in total thyroidectomy with central neck dissection.Frontiers in endocrinology · 2025Article
- Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy, characterized by a range of subtypes that differ in their cytologic features, clinical behavior, and prognosis. Accurate cytologic evaluation of PTC using fine-needle aspiration is essential but can be challenging due to the morphologic diversity among subtypes. This review focuses on the distinct cytologic characteristics of various PTC subtypes, including the classic type, follicular variant, tall cell, columnar cell, hobnail, diffuse sclerosing, Warthin-like, solid/trabecular, and oncocytic PTCs. Each subtype demonstrates unique nuclear features, architectural patterns, and background elements essential for diagnosis and differentiation from other thyroid lesions. Recognizing these distinct cytologic patterns is essential for identifying aggressive subtypes like tall cell, hobnail, and columnar cell PTCs, which have a higher risk of recurrence, metastasis, and poorer clinical outcomes. Additionally, rare subtypes such as diffuse sclerosing and Warthin-like PTCs present unique cytologic profiles that must be carefully interpreted to avoid diagnostic errors. The review also highlights the cytologic indicators of lymph node metastasis and high-grade features, such as differentiated high-grade thyroid carcinoma. The integration of molecular testing can further refine subtype diagnosis by identifying specific genetic mutations. A thorough understanding of these subtype-specific cytologic features and molecular profiles is vital for accurate diagnosis, risk stratification, and personalized management of PTC patients. Future improvements in diagnostic techniques and standardization are needed to enhance cytologic evaluation and clinical decision-making in thyroid cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.